首页> International journal of hematology> Marked improvement of platelet transfusion refractoriness after bortezomib therapy in multiple myeloma.

Marked improvement of platelet transfusion refractoriness after bortezomib therapy in multiple myeloma.

导出 LinkOut

翻译打印收藏纠错

第一作者： Hirokazu,Miki

第一单位： Department of Medicine and Bioregulatory Sciences, The University of Tokushima Graduate School of Health Biosciences, 3-18-15 Kuramoto, Tokushima, 770-8503, Japan.;Department of Hematology, Tokushima University Hospital, Tokushima, Japan.

作者： Hirokazu,Miki ^[1] ; Shuji,Ozaki ^[2] ; Osamu,Tanaka ^[1] ; Etsuko,Lee ^[3] ; Tomomi,Takimoto ^[3] ; Hirofumi,Watanabe ^[3] ; Shiro,Fujii ^[1] ; Shingen,Nakamura ^[1] ; Kumiko,Kagawa ^[1] ; Kyoko,Takeuchi ^[1] ; Ken-Ichiro,Yata ^[1] ; Masahiro,Abe ^[1] ; Shoji,Kagami ^[3] ; Toshio,Matsumoto ^[4]

作者单位： Department of Medicine and Bioregulatory Sciences, The University of Tokushima Graduate School of Health Biosciences, 3-18-15 Kuramoto, Tokushima, 770-8503, Japan.;Department of Hematology, Tokushima University Hospital, Tokushima, Japan. ^[1] Department of Medicine and Bioregulatory Sciences, The University of Tokushima Graduate School of Health Biosciences, 3-18-15 Kuramoto, Tokushima, 770-8503, Japan. ozakishu@clin.med.tokushima-u.ac.jp.;Department of Hematology, Tokushima University Hospital, Tokushima, Japan. ozakishu@clin.med.tokushima-u.ac.jp.;Division of Transfusion Medicine, Tokushima University Hospital, Tokushima, Japan. ozakishu@clin.med.tokushima-u.ac.jp. ^[2] Division of Transfusion Medicine, Tokushima University Hospital, Tokushima, Japan. ^[3] Department of Medicine and Bioregulatory Sciences, The University of Tokushima Graduate School of Health Biosciences, 3-18-15 Kuramoto, Tokushima, 770-8503, Japan. ^[4]